PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33373731-9	2021	Rates of susceptibility to ceftaroline for ESBL-negative Escherichia coli (n = 442), Klebsiella pneumoniae (n = 381), and Klebsiella oxytoca (n = 103) were 92.1%, 93.2%, and 96.1%, respectively.	T 91825	27-38	EsbL	Escherichia coli	43-47	
34022417-9	2021	Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >=96.7% in all regions.	T 91825	87-98	EsbL	Escherichia coli	18-50	
24529941-6	2014	Ceftaroline-avibactam was very active against Escherichia coli and Klebsiella pneumoniae (MIC50/90, 0.03/0.06 and 0.06/0.25 mug/mL, respectively) including extended-spectrum beta-lactamase (ESBL) screen-positive phenotypes (MIC50/90, 0.06/0.12 and 0.12/1 mug/mL, respectively).	T 91825	0-11	EsbL	Escherichia coli	190-194	
25222304-15	2014	Ceftaroline exhibited good activity against non-ESBL phenotype strains of E. coli and Klebsiella spp.	T 91825	0-11	EsbL	Escherichia coli	48-52	
25222304-17	2014	CONCLUSION: Ceftaroline demonstrated potent in vitro activity when tested against S. aureus, S. pneumoniae, H. influenzae, beta-hemolytic streptococci and non-ESBL-phenotype E. coli and Klebsiella spp.	T 91825	12-23	EsbL	Escherichia coli	159-163	
24529941-9	2014	Ceftaroline-avibactam exhibited a broad-spectrum of in vitro activity against isolates from patients in the USA with ABSSSI including MRSA, beta-hemolytic streptococci, E. coli, and K. pneumoniae as well as ESBL screen-positive phenotype isolates and merits further study in clinical indications where these resistant organisms may be a concern.	T 91825	0-11	EsbL	Escherichia coli	207-211	
19349512-2	2009	However, the activity of ceftaroline cannot be solely relied upon for eradication of multidrug-resistant gram-negative isolates, such as Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, which represent a current clinical concern.	T 91825	25-36	EsbL	Escherichia coli	198-202	
19349512-6	2009	Ceftaroline exhibited a MIC range of 0.125 to 1,024 microg/ml and was reduced 2- to 512-fold by combination with tazobactam (4 microg/ml) for ESBL-producing strains.	T 91825	0-11	EsbL	Escherichia coli	142-146